Statement of Ownership (sc 13g)
14 February 2023 - 10:23PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
SCHEDULE
13G
(Rule
13d-102)
INFORMATION
TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE
13d-1(b) (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b)
(Amendment
No. )*
ZyVersa
Therapeutics, Inc.
(Name
of Issuer)
Common
Stock
(Title
of Class of Securities)
98987D102
(CUSIP
Number)
December
31, 2022
(Date
of Event Which Requires Filing of this Statement)
Check
the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐
Rule 13d-1(b)
☐
Rule 13d-1(c)
☒
Rule 13d-1(d)
*The
remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject
class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover
page.
The
information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18
of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall
be subject to all other provisions of the Act (however, see the Notes).
| 1. |
NAMES
OF REPORTING PERSONS
I.R.S.
IDENTIFICATION NUMBER OF ABOVE PERSONS (ENTITIES ONLY):
INCON
Co., Ltd.
000000000 |
| 2. |
CHECK
THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) ☐
(b)
☐ |
| 3. |
SEC
USE ONLY
|
| 4. |
CITIZENSHIP
OR PLACE OF ORGANIZATION
KOREA,
REPUBLIC OF |
NUMBER
OF
SHARES
BENEFICIALLY
OWNED BY EACH
REPORTING
PERSON WITH |
5. |
SOLE VOTING POWER
1,947,901
(includes 450,702 warrants) |
6. |
SHARED
VOTING POWER
0 |
7. |
SOLE DISPOSITIVE POWER
1,947,901
(includes 450,702 warrants) |
8. |
SHARED
DISPOSITIVE POWER
0 |
| 9. |
AGGREGATE
AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,947,901
(includes 450,702 warrants) |
| 10. |
CHECK
IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
|
| 11. |
PERCENT
OF CLASS REPRESENTED BY AMOUNT IN ROW 9
16.49% |
| 12. |
TYPE
OF REPORTING PERSON*
CO |
| *12. |
Category | |
Symbol |
| |
Broker Dealer | |
BD |
| |
Bank | |
BK |
| |
Insurance Company | |
IC |
| |
Investment Company | |
IV |
| |
Investment Adviser | |
IA |
| |
Employee Benefit Plan, Pension Fund, or Endowment Fund | |
EP |
| |
Parent Holding Company/Control Person | |
HC |
| |
Savings Association | |
SA |
| |
Church Plan | |
CP |
| |
Corporation | |
CO |
| |
Partnership | |
PN |
| |
Individual | |
IN |
| |
Other | |
OO |
Item
1(a).
Name
of Issuer
ZyVersa
Therapeutics, Inc. (f/k/a Larkspur Health Acquisition Corp.)
Item
1(b).
Address
of Issuer’s Principal Executive Offices
2200
N. Commerce Parkway, Suite 208, Weston, Florida 33326.
Item
2(a).
Name
of Person Filing
INCON
Co., Ltd.
Item
2(b).
Address
of Principal Business Office, or, if None, Residence
4/F
16-17 LS-RO 91BEON-GIL, DONGAN-GU ANYANG, GYEONGGI, KOREA, REPUBLIC OF 14042
Item
2(c).
Citizenship
KOREA,
REPUBLIC OF
Item
2(d).
Title
of Class of Securities
Common
Stock (par value $0.0001 per share) and Warrants
Item
2(e).
CUSIP
Number
98987D102
Item
3.
If
This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
Not
Applicable. This Schedule is being filed pursuant to Rule 13d-1(d).
☐
Broker or dealer registered under Section 15 of the Exchange Act;
☐
Bank as defined in Section 3(a)(6) of the Exchange Act;
☐
Insurance company as defined in Section 3(a)(19) of the Exchange Act;
☐
Investment company registered under Section 8 of the Investment Company Act;
☐
An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
☐
An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
☐
A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
☐
A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
☐
A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company
Act;
☐
Group, in accordance with Rule 13d-1(b)(1)(ii)(J).
Item
4.
Ownership
| a. | Amount
Beneficially Owned: |
| | | 1,947,901
(includes 450,702 warrants) |
| b. | Percent
of Class: |
| | | 16.49% |
| c. | Number
of shares as to which reporting person has: |
| | | (i) |
Sole Voting Power: |
1,947,901(includes 450,702 warrants) |
| | | (ii) |
Sole voting power: |
0 |
| | | (iii) |
Sole
dispositive power: |
1,947,901 (includes 450,702 warrants) |
| | | (iv) |
Shared
dispositive power: |
0 |
Item
5.
Ownership
of Five Percent or Less of a Class
Not
Applicable
Item
6.
Ownership
of More Than Five Percent on Behalf of Another Person
Not
Applicable
Item
7.
Identification
and Clarification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company
Not
Applicable
Item
8.
Identification
and Classification of Members of the Group
Not
Applicable
Item
9.
Notice
of Dissolution of Group
Not
Applicable
Item
10.
Certification
This
Schedule is being filed pursuant to 13d-1(d).
By
signing below we certify that, to the best of our knowledge and belief, the securities referred to above were not acquired and are not
held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired
and are not held in connection with or as a participant in any transaction having that purpose of effect.
SIGNATURE
After
reasonable inquiry and to the best of the undersigned’s knowledge and belief, the undersigned certify that the information set
forth in this statement is true, complete and correct.
| |
February 14, 2023 |
| |
(DATE) |
| |
|
| |
INCON Co., Ltd. |
| |
|
| |
By: |
/s/ Seung Ku Jeon |
| |
Name: |
Seung Ku Jeon |
| |
Title: |
Chief Financial Officer |
| |
|
| |
/s/ Seung Ku Jeon |
| |
Seung Ku Jeon |
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Dec 2024 to Jan 2025
ZyVersa Therapeutics (NASDAQ:ZVSA)
Historical Stock Chart
From Jan 2024 to Jan 2025
